Ajanta Pharma net profit up 23 percent at Rs 159 crore in Q4

Published On 2021-05-02 03:30 GMT   |   Update On 2021-05-02 03:30 GMT
Advertisement

New Delhi: Drug firm Ajanta Pharma on Friday reported a 23 per cent rise in consolidated net profit to Rs 159 crore for the quarter ended March 2021 on account of robust sales.

The company had posted a net profit of Rs 129 crore for the corresponding period of the previous fiscal, Ajanta Pharma said in a regulatory filing.

Consolidated revenue from operations stood at Rs 757 crore for the quarter under consideration. It was Rs 682 crore in the year ago period, it added.

Advertisement

Read also: Aurobindo Pharma net profit jumps over 4-fold to Rs 2,946.32 crore in Q3

For the fiscal year ended March 2021, the net profit of the company was at Rs 654 crore compared to Rs 468 crore in the previous financial year, the filing said.

Revenue from operations came in at Rs 2,890 crore for 2020-21. It was Rs 2,588 crore for the previous financial year, it added.


Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News